By Billy Candra 
Physicians dedicated to the long-term well-being of childhood cancer survivors now have a clearer, more quantified understanding of the factors driving the risk for secondary cancers later in life. A groundbreaking study from scientists at St. Jude Children’s Research Hospital reveals that a survivor’s genetic makeup, alongside their life-saving initial cancer treatments, plays a significant and measurable role in determining their susceptibility to subsequent malignancies. This critical finding, published today in The Lancet Oncology, marks the first time researchers have been able to attribute the proportional contributions of these diverse factors at a population level, addressing a major knowledge gap in the field of survivorship. Secondary cancers represent the primary cause of mortality for long-term survivors of childhood cancer, making this research pivotal for enhancing preventive strategies and improving patient outcomes.
The study leverages the unparalleled depth and breadth of data from two of the world’s premier childhood cancer survivor cohorts: the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS), both primarily housed and managed at St. Jude. The combined datasets, representing thousands of survivors, provided an unprecedented opportunity to dissect the complex interplay of treatment exposures, genetic predispositions, and lifestyle factors in the development of secondary cancers.
The Evolving Landscape of Childhood Cancer Survivorship
Decades ago, a diagnosis of childhood cancer was often a grim prognosis. However, advancements in medical science have dramatically transformed this reality. Survival rates for children with cancer have soared from approximately 50% in the 1970s to over 80% today, with some specific cancer types boasting even higher cure rates. This remarkable progress, while celebrated, has brought forth a new set of challenges for the medical community: the long-term health consequences, or "late effects," faced by these survivors. These late effects can manifest in various forms, including cardiac issues, cognitive impairments, endocrine dysfunction, and perhaps most significantly, the development of secondary cancers.
Secondary malignant neoplasms (SMNs), or secondary cancers, are entirely new cancers that develop in survivors after their initial primary cancer treatment. Unlike a recurrence of the original cancer, SMNs arise independently and are often more aggressive and difficult to treat. Their emergence represents a tragic irony for individuals who have already endured the arduous journey of childhood cancer treatment. Understanding and mitigating the risk of SMNs has thus become a paramount focus in survivorship research and clinical care, directly impacting the quality and length of life for a growing population of survivors.
Prior research had established associations between certain treatment exposures (like radiation and specific chemotherapies), genetic predispositions, and lifestyle factors with an increased risk of secondary cancers. However, these factors were often studied in isolation, making it impossible to ascertain their relative importance or the proportion of risk each contributed across the survivor population. This lack of quantitative understanding hindered the development of truly personalized risk assessment and surveillance protocols.
Unpacking the Contributions: A Landmark Study
To address this critical knowledge gap, St. Jude scientists undertook an ambitious comparative analysis involving more than 10,000 survivors from the St. Jude LIFE and CCSS cohorts. Collectively, this represents the largest survivor cohort in North America with extensive genetic sequencing data, making the study uniquely powerful. The comprehensive dataset included detailed records of initial cancer diagnoses, specific treatment exposures (e.g., radiation fields and doses, types and cumulative doses of chemotherapy), extensive genetic information (including hundreds of common genetic variants and some rare ones), lifestyle factors (such as diet and exercise), and, crucially, the presence or absence of a secondary cancer. This holistic approach allowed researchers to build a robust model for evaluating the proportional contribution of each factor to the occurrence of secondary cancers.
"We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition," stated corresponding author Yadav Sapkota, PhD, from the St. Jude Department of Epidemiology and Cancer Control. "We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level." This quantification is a significant leap forward, providing actionable data for clinicians.
Co-author Greg Armstrong, MD, MSCE, chair of the St. Jude Department of Epidemiology and Cancer Control, underscored the unique capabilities afforded by the combined cohorts: "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing." The sheer volume and quality of data were instrumental in achieving the study’s precision.
Radiation: A Known Foe, Now Quantified
Among the factors analyzed, radiation exposure emerged as the most significant contributor to secondary cancer risk, accounting for approximately 40% or more of the overall risk. This finding strongly corroborates decades of prior research highlighting the long-term adverse effects of therapeutic radiation, particularly its role in inducing secondary malignancies. Historically, radiation therapy was a cornerstone of childhood cancer treatment, often delivered at high doses and to broad fields to ensure tumor eradication. However, as understanding of its late effects grew, there has been a concerted effort in modern oncology to de-escalate radiation doses, use more targeted delivery techniques (such as proton therapy), or entirely remove radiation from treatment protocols when other effective therapies are available. This study provides further robust evidence supporting these ongoing shifts in clinical practice, validating the efforts to minimize radiation exposure in pediatric cancer patients. The quantification of its contribution underscores the importance of continued vigilance in optimizing treatment protocols to maintain high cure rates while simultaneously reducing long-term toxicities.
Chemotherapy and the Surprising Role of Genetics
While the impact of radiation was relatively straightforward and largely consistent with existing knowledge, the researchers uncovered more complex and nuanced relationships when examining the contributions of chemotherapy and genetic predisposition. Chemotherapy, depending on the specific type of cancer and the agents used, contributed between 8% to 35% of subsequent cancer risk. The potential late effects of various chemotherapeutic agents have been well-documented, influencing treatment selection and follow-up care.
However, the contribution of genetic predisposition to secondary cancer risk in survivors was less well-recognized and, in some cases, surprisingly substantial. To better understand this predisposition, the researchers investigated hundreds of common genetic variants previously linked to cancer development in the general population, which are collectively summarized in a "polygenic risk score" (PRS). They also examined the influence of some rare genetic variants. The analysis of these genetic markers in St. Jude LIFE and CCSS participants revealed that, depending on the specific type of secondary cancer, the polygenic risk score contributed to a significant 5% to 37% of the risk.
This finding challenges conventional wisdom in the field. "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field," Sapkota revealed. This revelation has profound implications for how clinicians might assess and manage risk in the future, suggesting that a survivor’s inherent genetic susceptibility might be as critical, or even more critical, than their chemotherapy history for certain types of secondary malignancies.
Co-author Yutaka Yasui, PhD, also from the St. Jude Department of Epidemiology and Cancer Control, elaborated on the utility of PRS: "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population. Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures." This indicates that while PRS might not yet be universally precise enough for general population screening, their application within the high-risk cohort of childhood cancer survivors holds significant promise for clinical utility.
Lifestyle Factors: A Nuanced Perspective
In contrast to radiation, chemotherapy, and genetics, lifestyle factors such as diet and exercise appeared to contribute much less to the risk of secondary cancers in this study, accounting for a modest 1% to 6% of the risk. This finding might seem counterintuitive given the well-established links between lifestyle and cancer risk in the general population. However, the researchers offered a crucial contextualization: the survivors in this study were primarily in their 20s and 30s. This relatively young age may mean that the long-term, cumulative effects of lifestyle choices on cancer development had not yet had sufficient time to become apparent.
Sapkota emphasized the ongoing importance of healthy living: "We know healthy lifestyle choices are important for survivors. In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac well-being, so it is still important for clinicians to encourage — and patients to seek — a healthy lifestyle." This highlights that while lifestyle’s direct quantifiable contribution to secondary cancer risk might be lower at younger ages, its overall impact on a survivor’s health and well-being remains critical, influencing other late effects and general quality of life.
Expert Perspectives on the Paradigm Shift
The study’s findings are expected to catalyze a paradigm shift in how long-term follow-up care for childhood cancer survivors is approached. "Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk," Sapkota noted. "Our study suggests that we need to better account for genetic predisposition in this population."
This shift has direct implications for clinical practice. Oncologists and primary care physicians caring for this vulnerable population may need to integrate genetic screening into their long-term follow-up protocols. Identifying survivors with a strong genetic predisposition could enable more personalized and intense cancer surveillance strategies, such as more frequent imaging, targeted screenings, or earlier initiation of preventive measures. The goal is to detect any secondary cancer at its earliest, most treatable stage, significantly improving the chances of a favorable outcome.
Beyond the medical community, these findings also empower survivors themselves. Armed with knowledge of their unique combination of treatment-related, genetic, and lifestyle risk factors, survivors can become more informed advocates for their own health. They can engage in more proactive discussions with their healthcare providers about the necessity of tailored screening schedules and preventive interventions, fostering a collaborative approach to their ongoing care.
Toward Personalized Surveillance: Reshaping Clinical Practice
The implications of this research extend far beyond academic understanding; they are poised to directly influence clinical guidelines and patient care. The move towards truly personalized medicine in survivorship care means that a "one-size-fits-all" approach to surveillance for secondary cancers is increasingly outdated. Instead, the future of survivor care will likely involve:
- Comprehensive Risk Assessment: Integrating detailed treatment histories with advanced genetic profiling (including polygenic risk scores and screening for rare pathogenic variants) at key junctures in a survivor’s life.
- Tailored Screening Protocols: Developing individualized surveillance plans based on a survivor’s specific risk profile. For example, a survivor with high radiation exposure and a high genetic predisposition for breast cancer might begin mammography and MRI screening earlier and more frequently than a survivor with lower risk factors.
- Enhanced Patient Education: Providing survivors with clear, understandable information about their personal risk factors, empowering them to make informed decisions and actively participate in their own health management.
- Targeted Prevention Strategies: For those identified with very high genetic risks, exploring novel preventive strategies, which could range from lifestyle modifications (even if effects are delayed) to prophylactic interventions in certain extreme cases.
- Interdisciplinary Collaboration: Fostering closer collaboration between pediatric oncologists, adult oncologists, genetic counselors, primary care physicians, and other specialists to ensure seamless, lifelong, and risk-stratified care.
Empowering Survivors and Informing Future Research
"Second cancers remain the leading cause of mortality for childhood cancer survivors," Sapkota reiterated. "Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives." This quantification is not merely an academic exercise; it provides a roadmap for future interventions and research.
The study opens several avenues for further investigation. Researchers will continue to refine polygenic risk scores, exploring their predictive power for an even broader spectrum of secondary cancers. There is also a critical need to investigate gene-environment interactions – how specific genetic predispositions might amplify or mitigate the effects of particular treatment exposures. Longitudinal studies following survivors over even longer periods will be essential to fully understand the delayed impact of lifestyle factors and the evolving landscape of risk throughout adulthood. Furthermore, research into the ethical considerations of widespread genetic testing in this population – including issues of informed consent, potential psychological distress, and equitable access to advanced screening and counseling – will be paramount.
Ultimately, this landmark study from St. Jude Children’s Research Hospital offers a beacon of hope for childhood cancer survivors. By providing a clearer picture of their individual risks, it paves the way for a more precise, personalized, and proactive approach to long-term care, ultimately aiming to reduce the burden of secondary cancers and enable survivors to live longer, healthier lives.
Authors and Funding
The study’s first author is Achal Neupane, of St. Jude. The study’s other authors are Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison and Yutaka Yasui from St. Jude; Qi Liu from the University of Alberta; Cindy Im, Lucie Turcotte and Joseph Neglia from the University of Minnesota; Monica Gramatges from Baylor College of Medicine; Rebecca Howell from the University of Texas MD Anderson Cancer Center; and Smita Bhatia from the University of Alabama at Birmingham.
The study received support from grants from the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547 and CA21765) and ALSAC, the fundraising and awareness organization of St. Jude.
